OnKure Therapeutics (NASDAQ:OKUR - Get Free Report)'s stock had its "buy" rating reissued by research analysts at HC Wainwright in a report released on Friday,Benzinga reports. They currently have a $40.00 price objective on the stock. HC Wainwright's target price indicates a potential upside of 127.53% from the stock's current price.
A number of other equities research analysts have also recently commented on OKUR. Lifesci Capital upgraded shares of OnKure Therapeutics to a "strong-buy" rating in a report on Thursday, October 10th. Oppenheimer began coverage on OnKure Therapeutics in a research note on Thursday, October 10th. They set an "outperform" rating and a $35.00 price target on the stock.
Read Our Latest Stock Report on OKUR
OnKure Therapeutics Stock Performance
Shares of NASDAQ:OKUR traded up $0.39 during mid-day trading on Friday, reaching $17.58. 29,108 shares of the company's stock were exchanged, compared to its average volume of 30,611. OnKure Therapeutics has a twelve month low of $9.80 and a twelve month high of $77.60. The firm has a market cap of $58.72 million, a PE ratio of -1.05 and a beta of 0.21.
OnKure Therapeutics (NASDAQ:OKUR - Get Free Report) last announced its earnings results on Thursday, November 7th. The company reported ($1.10) EPS for the quarter, missing the consensus estimate of ($0.97) by ($0.13). Sell-side analysts forecast that OnKure Therapeutics will post -3.87 EPS for the current year.
About OnKure Therapeutics
(
Get Free Report)
Reneo Pharmaceuticals Incis a clinical stage pharmaceutical company. It is focused on the development and commercialization of therapies for patients with rare, genetic, mitochondrial diseases. Reneo Pharmaceuticals Incis based in SAN DIEGO.
Featured Stories
Before you consider OnKure Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and OnKure Therapeutics wasn't on the list.
While OnKure Therapeutics currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Click the link below and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
